How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,106 results for

Subcutaneous Fat Necrosis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Management of Dyslipidaemias Full Text available with Trip Pro

lipoprotein cholesterol levels 25 7.4 Lifestyle recommendations to improve the plasma lipid profile 25 7.4.1 Body weight and physical activity 25 7.4.2 Dietary fat 25 7.4.3 Dietary carbohydrate and fibre 26 7.4.4 Alcohol 26 7.4.5 Smoking 26 7.5 Dietary supplements and functional foods for the treatment of dyslipidaemias 26 7.5.1 Phytosterols 26 7.5.2 Monacolin and red yeast rice 26 7.5.3 Dietary fibre 27 7.5.4 Soy 27 7.5.5 Policosanol and berberine 27 7.5.6 n-3 unsaturated fatty acids 27 8 Drugs (...) TGs Triglycerides TIA Transient ischaemic attack TIMI Thrombolysis In Myocardial Infarction TNF Tumour necrosis factor TNT Treating to New Targets TRL Triglyceride-rich lipoprotein ULN Upper limit of normal VA-HIT Veterans Affairs High Density Lipoprotein Intervention Trial VITAL VITamin D and OmegA-3 Trial VLDL Very low-density lipoprotein WHO World Health Organization WOSCOPS West of Scotland Coronary Prevention Study 1 Preamble Guidelines summarize and evaluate available evidence with the aim

2019 European Society of Cardiology

102. Management of Poisoning

with ingestions of propionic acids (ibuprofen), pyrazolones (phenylbutazone), acetic acids (diclofenac and indomethacin), and anthranilic acids (mefenamic acid and meclofenamate). (2) Seizures are eff ectively treated with benzodiazepines. • Renal toxicity: – Acute forms of renal insuffi ciency or failure and renal papillary necrosis are rare in NSAID overdose. – Most commonly, these pathologic processes occur in patients with decreased eff ective arterial volume (congestive heart failure, cirrhosis

2020 Ministry of Health, Singapore

103. New Direct-acting Antiviral for Hepatitis C (Epclusa?

(90,000 USD)/24 weeks Page 4 · MED CHECK April 2019/ Vol.5 No.13 New Products New Products Known facts Hepatitis C virus (HCV) interferes with utilization of triglyceride to form lipoprotein in hepatocytes and causes fatty liver and hepatocellular necrosis, leading to liver cirrhosis and hepatic cancer over a long period of time. Table 1a is a summary of direct-acting antivirals (DAAs) which have been approved in Japan in prior to the approval of the new combination: sofosbuvir (SOF) and velpatasvir (...) , and causes fatty liver. As a result, hepatocellular function and glucose metabolism are impaired, leading to hepatocellular necrosis [4,5]. When HCV turns negative, hepatocellular function and glucose metabolism improve. Therefore, if hypoglycemic agents are not reduced or discontinued, hypoglycemia might occur. Cited from Ref.1 and revised by MedCheck DAAs: direct-acting antivirals comb Tab: combination tablet, comb. Tx: combination therapy ASV:Asunaprevir, BCV:Beclabuvir, DCV: Daclatasvir, EBV:Elbasvir

2019 Med Check - The Informed Prescriber

104. Critical Assessment of Diabetes Guidelines

(90,000 USD)/24 weeks Page 4 · MED CHECK April 2019/ Vol.5 No.13 New Products New Products Known facts Hepatitis C virus (HCV) interferes with utilization of triglyceride to form lipoprotein in hepatocytes and causes fatty liver and hepatocellular necrosis, leading to liver cirrhosis and hepatic cancer over a long period of time. Table 1a is a summary of direct-acting antivirals (DAAs) which have been approved in Japan in prior to the approval of the new combination: sofosbuvir (SOF) and velpatasvir (...) , and causes fatty liver. As a result, hepatocellular function and glucose metabolism are impaired, leading to hepatocellular necrosis [4,5]. When HCV turns negative, hepatocellular function and glucose metabolism improve. Therefore, if hypoglycemic agents are not reduced or discontinued, hypoglycemia might occur. Cited from Ref.1 and revised by MedCheck DAAs: direct-acting antivirals comb Tab: combination tablet, comb. Tx: combination therapy ASV:Asunaprevir, BCV:Beclabuvir, DCV: Daclatasvir, EBV:Elbasvir

2019 Med Check - The Informed Prescriber

106. Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis

subcutaneous injection. Methotrexate should be continued during treatment with Hyrimoz. Glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs, or analgesics can be continued during treatment with Hyrimoz. Regarding combination with disease modifying anti-rheumatic drugs other than methotrexate see sections 4.4 and 5.1. 5 In monotherapy, some patients who experience a decrease in their response to Hyrimoz 40 mg every other week may benefit from an increase in dosage to 40 mg adalimumab every (...) with psoriatic arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection. Available data suggest that the clinical response is usually achieved within 12 weeks of treatment. Continued therapy should be reconsidered in a patient not responding within this time period. Psoriasis The recommended dose of Hyrimoz for adult patients is an initial dose of 80 mg administered subcutaneously, followed by 40 mg subcutaneously given every other week starting one week after

2018 European Medicines Agency - EPARs

107. Neratinib (Nerlynx) - Breast cancer, breast neoplasms

. Hepatic necrosis in 1/3 females. 700 mg/kg: no evidence of macroscopic changes. Assessment report EMA/CHMP/525204/2018 Page 25/169 RPT-48225 GLP Rat 3M:3F/Group 0, 200, 700, 2000 - IP 700/200 Mortality at 2000 & 700 mg/kg, with changes to adrenal gland, GI tract, and kidney. Renal tubular ectasia at 2000 mg/kg. 200 mg/kg: enlarged liver, fibrosis of stomach, small/large intestine, spleen, pancreas. In mice, no adverse effects were seen in doses of neratinib up to 2000 mg/kg. Single intraperitoneal (...) ), and signs of hepatic inflammation and necrosis. There were moderate increases in fibrinogen, white blood cells (WBC), neutrophils, lymphocytes, and monocytes, and decreases in cholesterol, total protein and albumin. Other findings High doses in the earlier dose-range finding studies in rats showed evidence of reproductive organ toxicity, prostatic and uterine atrophy leading to reduced prostate and uterus weights. In addition male rats experienced mammary gland atrophy (neratinib doses of =15 mg/kg/day

2018 European Medicines Agency - EPARs

108. Semaglutide (Ozempic) - Diabetes Mellitus

4.4, 4.5 and 5.1. Pharmaceutical form: solution for injection Strength: 1.34 mg/ml Route of administration: subcutaneous use Packaging: cartridge (glass) in pre-filled pen Package size: 1 pre-filled pen + 6 needles Ozempic Assessment report EMA/CHMP/715701/2017 Page 3/156 Table of contents 1. Background information on the procedure 7 1.1. Submission of the dossier 7 1.2. Steps taken for the assessment of the product 8 2. Scientific discussion 9 2.1. Problem statement 9 2.1.1. Disease or condition (...) of exposure PYO patient year of observation RMP risk management plan RR rate ratio SAE serious adverse event SAP statistical analysis plan SBP systolic blood pressure s.c. sub cutaneous sema semaglutide SGLT-2 sodium-dependent glucose transporter two SMQ standardised MedDRA query SOC system organ class SU sulfonylurea SUSTAIN Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes T2D type 2 diabetes mellitus TNF-alpha tumour necrosis factor alpha TZD thiazolidinediones UACR urinary albumin

2018 European Medicines Agency - EPARs

109. Rucaparib camsylate - Ovarian Neoplasms

/kg BID rucaparib resulted in statistically significant inhibition of 45%, 86%, and 96% respectively. There was an inverse and dose-dependent correlation between PAR and rucaparib levels in the plasma and tumour. Although the tumour to plasma (T/P) ratio was lower at higher doses of rucaparib, the levels of rucaparib in the tumour were consistently higher than the levels of rucaparib in plasma. A further PK/PD study was performed in the subcutaneous MDA-MB-436 xenograft model. Animals were treated (...) lymph nodes, and thymic atrophy (correlated with decreased thymic weights at 75 mg/kg/day). Minimal to moderate myocardial degeneration, necrosis, and fibroplasia usually located at the apex of the heart were observed in males at 75 mg/kg/day. No associated changes in troponin T levels were noted on Day 6. The NOAEL for rucaparib in this study was considered to be 5 mg/kg/day, which corresponded to a mean combined male and female C max and AUC 0-24.5 of 672 ng/mL and 992 ng·hr/mL, respectively

2018 European Medicines Agency - EPARs

110. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn’s Disease

and biologic tumor necrosis factor antagonists for induction and maintenance therapy at diagnosis or at early stages of se- vere disease, and for patients failed by steroid and immunosuppressant induction therapies. The group recommended against the use of oral 5-aminosalicylate for induction or maintenance therapy in pa- tients with moderate disease, and recommended against thiopurines for induction therapy, cortico- steroids for maintenance therapy, and cannabis in any role. The group was unable (...) an important therapeutic goal. 5 This may be especially important in young patients, given the potential for growth impairment as a direct effect of persistent chronic in- flammation 6,7 and their long lives ahead, during which disease complications may occur. Mucosal healing became a realistic goal for patients with the advent of monoclonal antibodies directed against tumor necrosis factor (TNF)-a. As alternate pathway biologic agents and new small molecule therapies emerge, it behooves clinicians

2019 Canadian Association of Gastroenterology

111. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease

to thiopurines. Despite the fact that certolizumab is FDA approved and used in the United States, it is not licensed for the treatment of CD in Canada or Europe and therefore was not included in this CPG. AZA, azathioprine; IM, intramuscular; MTX, methotrexate; SC, subcutaneous; TNF, tumor necrosis factor. e8 Journal of the Canadian Association of Gastroenterology, 2019, Vol. 2, No. 3T able 3. Summary of Consensus Recommendations for the Management of Luminal Crohn’s Disease a Disease activity 1. We (...) budesonide) can be used as induction, but not mainten- ance therapies. Among immunosuppressants, thiopurines should not be used for induction, but can be used for maintenance therapy for selected low-risk patients. Parenteral methotrexate was proposed for induction and maintenance therapy in patients with corticosteroid-dependent CD. Biologic agents, including tumor necrosis factor antagonists, vedolizumab, and ustekinumab, were recommended for patients failed by conventional induction therapies

2019 Canadian Association of Gastroenterology

112. Management of Rheumatod Arthritis

habit includes the following: • consume more fresh fruits and vegetables • reduce sugar and salt • avoid processed food and high saturated fat diet • if you drink alcohol, do so in moderation; some people on certain RA medications may need to avoid alcohol completely IV. Emotional health Living with RA can be a challenge. It is normal to feel angry or frustrated because tasks that used to be done routinely may now be difficult. Emotional stress may make it harder to deal with pain. Some steps

2019 Ministry of Health, Malaysia

113. A cost-utility analysis of biosimilar infliximab compared to reference infliximab in adult switch patients with Crohn’s disease: A Canadian analysis

in children, and high intake of total fat, polyunsaturated fatty acids, omega 6 fatty acids and red meat (Crohn's and Colitis Foundation of Canada, 2012). All of these factors may in part explain the high incidence and prevalence of CD in the Canadian environment. 1.4.3 Symptoms & Complications CD can lead to a number of symptoms and complications which affect both the intestinal tract and other parts of the body since it is a systemic disease (Gastrointestinal Society - Canadian Society of Intestinal (...) , & Lichtenstein, 2014). It starts with therapies that are less costly and/or with more preferable routes of administration, but potentially less effective. It escalates to the therapies which are more effective, but also more costly and with intravenous or subcutaneous administration (Lin et al., 2014). If a patient fails one level of therapy or becomes intolerant they are moved up to the next strategy (Lin et al., 2014). However, using this method also means that effective therapy may be delayed, with a risk

2019 SickKids Reports

115. ACR–ASNR–SPR Practice Parameter for the Performance of Magnetic Resonance Imaging (MRI) of the Head and Neck

for delineating fine anatomic detail when the structure in question is surrounded by soft tissue or when fat- containing tissue is present [9]. For structures surrounded by cerebrospinal fluid, such as the cranial nerves in the cisterns and internal auditory canals, thin, 3-D T2-weighted images provide excellent delineation of detail [10]. Fast spin-echo (FSE) T2-weighted imaging (long TR/long TE FSE) or equivalent sequences demonstrate greater detail in a shorter time than conventional T2-weighted imaging (...) and is favored in the head and neck as physiologic and gross patient motion commonly degrade images [11,12]. As fat remains hyperintense on T2-weighted FSE images, and because of the amount of fat in the head and neck, using fat-suppression techniques such as frequency-selective fat saturation, chemical selective partial inversion recovery (SPIR), Dixon-type fat- suppression techniques, or short tau inversion recovery (STIR) produces images with better delineation of pathology [11,13,14]. Diffusion-weighted

2019 American Society of Neuroradiology

117. Heart Disease and Stroke Statistics Full Text available with Trip Pro

tax was greatest among households of the lowest socioeconomic status. A similar 1 cent per ounce excise tax on SSBs was implemented in Berkeley, California, in January 2015, and SSB sales declined by 9.6% after 1 year compared with predicted SSB purchases based on pretax trends. The Special Supplemental Nutrition Program for Women, Infants, and Children food package was revised in 2009 to include more fruits, vegetables, whole grains, and lower-fat milk. These food package revisions were

2019 American Heart Association

118. Radiation Therapy for the Whole-Breast (ASTRO)

or excellent in approximately 70% of women in both groups. There were similarly no reported differences in 10-year skin and subcutaneous tissue complications. The Royal Marsden Hospital and Gloucestershire Oncology Centre (RMH/GOC), or Standardization of Breast Radiotherapy (START) pilot trial, was a three-arm trial that used 3900 cGy or 4290 cGy in 13 fractions, compared to 5000 cGy in 25 fractions, all delivered in 5 weeks. 3,4 Eligibility was T1-3, N0-1, age 1 mm. A tumor bed boost was permitted

2019 American Society for Radiation Oncology

119. Type 2 Diabetes Mellitus and Heart Failure Full Text available with Trip Pro

chronic kidney disease; CVD, cardiovascular disease; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate (in mL·min −1 ·1.73 m −2 ); FDA, US Food and Drug Administration; GLP-1, glucagon-like peptide-1; HF, heart failure; LDL, low-density lipoprotein cholesterol; NPH, neutral protamine Hagedorn; SC, subcutaneous; and SGLT-2, sodium glucose cotransporter type 2. *Data to support this association are limited, and several studies, including a large prospective trial (UKPDS [UK (...) -1 receptor agonists are administered subcutaneously and can be given alone or in addition to other glucose-lowering agents, including insulin. In large-scale postmarketing cardiovascular outcomes trials required by the FDA to demonstrate the cardiovascular safety of glucose-lowering medications, GLP-1 receptor agonists have shown mostly beneficial effects on cardiovascular outcomes but no effect on HF hospitalization ( ; ). In the ELIXA RCT (Evaluation of Lixisenatide in Acute Coronary Syndrome

2019 American Heart Association

120. AACE/ACE Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care

challenges because GH is a naturally occurring substance which has a short half-life after subcutaneous and intrave- nous injection, is released in a pulsatile fashion, and the levels increase after exercise. Drug testing involv- ing urine sampling is not recommended as this method of testing has not been shown to be accurate and reli- able, whereas repeated blood sampling over 24-hours is neither practical nor feasible in the sports setting (Grade A; BEL 1). R57. In the U.S., off-label distribution (...) for the recommendations in the Executive Summary. Q1. WHAT IS ADULT GHD? Adult GHD is a well-defined clinical entity character - ized by decreased lean body mass and increased fat mass, dyslipidemia, cardiac dysfunction, decreased fibrinolysis and premature atherosclerosis, decreased muscle strength and exercise capacity, decreased bone mineral density (BMD), increased insulin resistance, and impaired QoL (54). Recent studies have demonstrated increased mortality in patients with hypopituitarism (37,55-59

2019 American Association of Clinical Endocrinologists

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>